Second Symposium of Novel Molecular Targets for Cancer Therapy

Oncologist

Volumn 7, Issue SUPPL. 3, 2002, Pages 1-3

  Frijhoff, Anita F W ^a   Conti, Claudio J ^a   Senderowicz, Adrian M ^b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Angiogenesis; Antineoplastic agents; Cell cycle; Clinical trials; Molecular targets; Therapy related cancer

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; DNA; FLAVOPIRIDOL; IMATINIB; LIGAND; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; PROTEINASE; RNA; TUBULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RESEARCH; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; DRUG TARGETING; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; MELANOMA; MOLECULAR BIOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETINOBLASTOMA; SIGNAL TRANSDUCTION; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; ANIMAL; NEOPLASM; ONCOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 0036056547     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_3-1     Document Type: Conference Paper

References (27)

1. First symposium of novel molecular targets for cancer therapy
2. New molecular targets for anticancer therapy
3. Vascular endothelial growth factor: Regulation in the mouse skin carcinogenesis model and use in antiangiogenesis Cancer Therapy
4. Tumor angiogenesis: Therapeutic implications
5. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
6. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
7. Spontaneous Ha-ras gene activation in cultured primary murine keratinocytes: Consequences of Ha-ras gene activation in malignant conversion and malignant progression
8. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
9. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
10. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
11. The cell cycle as a target for cancer therapy: Basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01
12. Cancer cell cycles
13. The retinoblastoma protein and cell cycle control
14. Small molecule modulators of cyclin-dependent kinases for cancer therapy
15. Preclinical and clinical development of cyclin-dependent kinase modulators
16. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
17. Phase I clinical and pharmacokinetic trial of flavopiridol
18. Clinical trials referral resource. Clinical trials of flavopiridol
19. The cyclin-dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer
20. A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer
21. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results
22. Cell cycling, BCL2, and p53 effects on flavopiridol-paclitaxel interactions in non-small cell lung cancer (NSCLC) cell lines
23. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
24. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
25. Cancer vaccines
26. Cytotoxic agents in the era of molecular targets and genomics
27. On receptor inhibitors and chemotherapy